NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market on Wednesday that its fourth-quarter revenues declined 6 percent and it swung from a profit in the 2007 fourth quarter to a loss.

The Omaha, Neb.-based pharmacogenomics assay developer and lab services firm had revenues of $6.1 million for the three-month period ended December 31, compared to revenues of $6.5 million for the fourth quarter of 2007.

It swung to a net loss of $219,000, or $.00, per share, from a profit of $212,000, or $.00 per share, in the fourth quarter of 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.